Posted: Wed Feb 25, 2009 8:34 am
.
Welcome to This is MS, the leading forum for Multiple Sclerosis research and support. Join our friendly community of patients, caregivers, and researchers celebrating over 20 years of delivering hope through knowledge.
https://www.thisisms.com/forum/
One of the bigest issues in the medical world is increasing specialization so that a doctor from one field does not have enough background to understand what is going on in another. They simply refer.They do not even know what is going on in the world of doppler technology and 7Tesla MRI
what about all the crab's it's a shame for all the folks on thembecause nothing else works
Document title
Endothelium and venotropic drugs in chronic venous insufficiency: A review
Author(s)
MICHIELS C. ; REMADE J. ; BOUAZIZ N. ;
Abstract
Objective: To review the literature concerning chronic venous disease of the leg and the mechanisms of action of venotropic drugs. Methods: The authors identified relevant papers from their own collection and from medical literature databases. Synthesis: Endothelial cell activation caused by exposure to the hypoxic conditions that develop during blood stasis in chronic venous insufficiency patients is proposed to be one factor initiating a pro-inflammatory process in the leg veins. Recruited and activated neutrophils would then be responsible for alterations of the venous wall, typical of what is observed in varicose veins. Venotropic drugs used in the treatment of chronic venous insufficiency patients have long been known to decrease vascular permeability and increase venous tone. Recently, it has been shown that they are also able to prevent endothelial cell activation by hypoxia and a precise biochemical target common to all of them has been identified: the mitochondrial respiratory chain. Conclusion: The influence of venotropic drugs on the mitochondrial respiratory chain provides a rational explanation for the therapeutic benefit to patients of this class of drugs.
Journal Title
Phlebology ISSN 0268-3555
Source
2002, vol. 17, no3-4, pp. 145-150 [6 page(s) (article)]
This thread is huge so rather than say read it all I will tell you that:Is this doctor doing any kind of trials? The information is so vauge. If this was the US, we could contact the hospital or university to get more information on any research and trials. I see a lot of talk here but not much outside this website. No wonder my neuro pretty much just threw the papers I gave him in the trash. there has to be more to this.
Marie - I have seen that thread, thanks. It's a great thread, just like this one. And maybe I should post the info below in that thread, but I'm lazy....mrhodes40 wrote:Hub it looks good I am sure Cheer will be along to add more.......Have you seen the endothellial thread in regimens forum?
And glutathione measurements could help scientists unravel other disease mysteries, too. 'You name the disease, you can postulate mitochondrial involvement,' Enns said. 'It's been proposed for everything from poor vision to hearing loss, kidney disease, liver disease, autism spectrum disorders, diabetes, Alzheimer disease, cancers. Our work could lead to research on therapies for a broad range of disorders.'
Thanks, Hub! Interesting stuff. Looks like the mitochondria are the power source for cells, and that they are part of the endothelium. (Boy, do I wish I'd paid more attention in biology!) My research has focused on the endothelium, because that is the lining of the blood vessels, and I've followed the vascular route- including reducing hypercoagulation & inflammation, and hypertension.Hub wrote:.
Cheer -- the article focuses on a breakthrough that occurred at Stanford. Since you're going there in March, I thought you might be interested (if you're persuaded by the line of thought that emphasizes mitochondrial function in MS).
Here's the link:
<shortened url>
This is from the study you posted on the varicose vein treatment...the drug works by stopping oxygen to the endothelial cells and halting venous damage via the mitochondrial respiratory chain. Have to take their word for it!Recently, it has been shown that they are also able to prevent endothelial cell activation by hypoxia and a precise biochemical target common to all of them has been identified: the mitochondrial respiratory chain. Conclusion: The influence of venotropic drugs on the mitochondrial respiratory chain provides a rational explanation for the therapeutic benefit to patients of this class of drugs.
linkThere are no cures for mitochondrial diseases, but treatment can help reduce symptoms, or delay or prevent the progression of the disease.
Treatment is individualized for each patient, as doctors specializing in metabolic diseases have found that every child and adult is "biochemically different." That means that no two people will respond to a particular treatment in a specific way, even if they have the same disease.
Certain vitamin and enzyme therapies, along with occupational and physical therapy, might be helpful for some patients.
Vitamins and supplements prescribed might include:
Coenzyme Q10
B complex vitamins: thiamine (B 1), riboflavin (B 2), niacin (B 3), B 6, folate, B 12, biotin, pantothenic acid
Vitamin E, lipoic acid, selenium, and other antioxidants
L-carnitine (Carnitor ®)
Intercurrent illness supplement: vitamin C, biotin
Other treatments that might be prescribed include:
Diet therapy, as prescribed by your doctor along with a registered dietitian, might be recommended.
Antioxidant treatments as protective substances are currently being investigated as another potential treatment method.
Cheer,cheerleader wrote:This is from the study you posted on the varicose vein treatment...the drug works by stopping oxygen to the endothelial cells and halting venous damage via the mitochondrial respiratory chain. Have to take their word for it!Recently, it has been shown that they are also able to prevent endothelial cell activation by hypoxia and a precise biochemical target common to all of them has been identified: the mitochondrial respiratory chain. Conclusion: The influence of venotropic drugs on the mitochondrial respiratory chain provides a rational explanation for the therapeutic benefit to patients of this class of drugs.